Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
You may not be if
Participants with primary platinum-refractory disease.
Clareo Health | A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
